Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis

New England Journal of Medicine

Volumn 365, Issue 22, 2011, Pages 2067-2077

  Saadoun, David ^a,b   Rosenzwajg, Michelle ^a,b,c,d   Joly, Florence ^f   Six, Adrien ^a,b,d   Carrat, Fabrice ^c,e   Thibault, Vincent ^d   Sene, Damien ^b   Cacoub, Patrice ^a,b,c,d   Klatzmann, David ^a,b,c,d  

^a SORBONNE UNIVERSITÉ   (France)

^b CNRS   (France)

^c INSERM   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f Prediguard   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2; RITUXIMAB;

ADULT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASTHENIA; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VASCULITIS; VIRUS LOAD;

EID: 82555196118     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1105143     Document Type: Article

References (29)

1. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988;240:1169-76.
2. Chang AE, Rosenberg SA. Overview of interleukin-2 as an immunotherapeutic agent. Semin Surg Oncol 1989;5:385-90. (Pubitemid 20052553)
3. Giedlin MA, Zimmerman RJ. The use of recombinant human interleukin-2 in treating infectious diseases. Curr Opin Biotechnol 1993;4:722-6. (Pubitemid 24001489)
4. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010;11:7-13.
5. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9. (Pubitemid 39273735)
6. Darrasse-Jèze G, Bergot AS, Durgeau A, et al. Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Invest 2009;119:2648-62.
7. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006;107:2409-14. (Pubitemid 43345561)
8. Lemoine FM, Cherai M, Giverne C, et al. Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. Int J Oncol 2009;35:569-81.
9. Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008;26:453-79. (Pubitemid 351600382)
10. Boyer O, Saadoun D, Abriol J, et al. CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood 2004;103:3428-30. (Pubitemid 38525674)
11. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum 1999;42:2204-12. (Pubitemid 30263607)
12. Lenzi M, Frisoni M, Mantovani V, et al. Haplotype HLA-B8-DR3 confers susceptibility to hepatitis C virus-related mixed cryoglobulinemia. Blood 1998;91:2062-6. (Pubitemid 28185509)
13. Saadoun D, Landau DA, Calabrese LH, Cacoub PP. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford) 2007;46:1234-42. (Pubitemid 47244492)
14. Saadoun D, Rosenzwajg M, Landau D, Piette JC, Klatzmann D, Cacoub P. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 2008;111:5334-41.
15. Landau DA, Rosenzwajg M, Saadoun D, Trébeden-Negre H, Klatzmann D, Cacoub P. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis. Arthritis Rheum 2008;58:2897-907.
16. Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010;116:326-34.
17. Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980;69:287-308. (Pubitemid 10036826)
18. Iman RL, Davenport JM. Approximations of the critical region of the Friedman statistic. Comm Statist Theory Methods 1980;9:571-95.
19. Conover WJ. Practical nonparametric statistics. 2nd ed. New York: John Wiley, 1980.
20. Chaput N, Louafi S, Bardier A, et al. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 2009;58:520-9.
21. Charles ED, Green RM, Marukian S, et al. Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood 2008;111:1344-56. (Pubitemid 351213421)
22. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011;331:44-9.
23. Comon P. Independent component analysis, a new concept? Signal Process 1994;36:287-314.
24. Koreth J, Matsuoka K-i, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365:2055-66.
25. Terrier B, Saadoun D, Sène D, et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum 2009;60:2531-40.
26. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009;119:1745-54.
27. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005;436:946-52. (Pubitemid 41191670)
28. Ait-Oufella H, Salomon BL, Potteaux S, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006;12:178-80. (Pubitemid 43214743)
29. Grinberg-Bleyer Y, Baeyens A, You S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010;207:1871-8.